ClinicalTrials.gg
WithdrawnNCT03641248Updated May 26, 2022

Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract

An Early Phase 1 interventional study of Enteric coated Devil's Claw and Non-enteric coated Devil's Claw in Osteoarthritis, Knee, sponsored by University of Missouri-Columbia. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-26.

Sponsored by University of Missouri-Columbia · Early Phase 1, Interventional, and Basic science

How we know

Why this study was withdrawn
Recruitment was not possible due to COVID19.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Enrollment
667th of 691
0 · median 72
Started
2021
with 59 others
Phase 1
38 of 796
4 open now
Registered
419th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 667th largest by enrollment of the 691 interventional ones that give a count, is one of 60 that started in 2021, is one of 38 in phase 1, and was the 419th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

Study will define the bioavailability and short term pharmacokinetics of the principal secondary metabolites of a aqueous-ethanolic extract of H. procumbens in non-enteric and enteric capsules.

Read the detailed description

The study(n = 12) will use a one-dose design to measure bioavailability and pharmacokinetic properties of an aqueous extract of H. procumbens containing 100mg harpagoside. Plasma levels of harpagoside, harpagide, verbascoside, and 8-p-coumarylharpagide will be measured for 24 hours with blood collections taken at timed intervals.

03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:- adult (at least 18 years of age);

  • diagnosed with knee osteoarthritis (OA) ;
  • (BMI) of less than 40;
  • willing to use only the study product, and Tramadol or Tylenol as a rescue pain medication over the course of their participation in the study;
  • willing and able to monitor blood glucose levels if diabetic;
  • willing to abstain from caffeine-containing drinks and food before coming into a study visit;
  • able to read and understand English and have the cognitive capacity to give consent;
  • willing to abstain from use of the following during participation in the study: prescription and over-the-counter non-steroidal anti-inflammatory medications, (e.g., aspirin, ibuprofen, Advil, Motrin, Nuprin, Naproxen, etc.); any dietary supplements (St. John's Wort, etc.); and, grapefruit and/or products containing it.

Exclusion Criteria:- cardiovascular disease, previous myocardial infarction, stent, coronary artery bypass graft (CABG), arrhythmia, high or low blood pressure;

  • recurrent stomach upset, or gastric or duodenal ulcers;
  • gallstones or gall bladder disease (cholelithiasis);
  • liver or kidney disease;
  • alcohol use of more than two drinks per day on a regular basis;
  • Coumadin or anti- drug use;
  • at risk for respiratory depression, history of seizures, or taking drugs that reduce the seizure threshold or may increase the risk for development of serotonin syndrome;
  • pregnant or breast feeding, or intention to become pregnant during the study;
  • pronounced allergies, or known allergy to study product or corn starch (placebo);
  • have had an injection to treat OA within the past three months;
  • currently taking NSAIDs, unless they are willing to stop for a 1-week ;
  • currently on a selective serotonin reuptake inhibitor (SSRI) but are poorly stabilized, or have evidence of suicidal ideation and/or suicide attempts in the past year; and,
  • reported use during the 7 days prior to study drug administration of: prescription and over-the-counter medications (e.g., NSAIDs), and any dietary supplements; grapefruit and/or its products; and, St. John's Wort.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Enteric coated Devil's Claw

    H. procumbens 100 mg in enteric coated capsules

    Drug: Enteric coated Devil's Claw

  • Active comparator
    Non-enteric coated Devil's Claw

    H. procumbens 100 mg in non-enteric coated capsules

    Drug: Non-enteric coated Devil's Claw

Interventions

06

What researchers measure

Primary outcomes

  1. Maximal concentration level of Devil's Claw metabolites, Cmax (ng/ml)

    Blood will be drawn at predefined intervals following administration of one dose of study drug

    Time frame: 0.5 hour, 1 hour, 2 hours, 2.5 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 12 hours

  2. Time to reach Cmax (h)

    Blood will be drawn at predefined intervals following administration of one dose of study drug

    Time frame: 0 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours

  3. Determination of terminal half-life of Devil's Claw, t 1/2 (h)

    Blood will be drawn at predefined intervals following administration of one dose of study drug

    Time frame: 0 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours

Secondary outcomes

  1. Change in plasma levels of harpagoside

    Blood will be drawn for Devil's Claws metabolites at Visit 2

    Time frame: 24 hours after dose of Devil's Claw

  2. Change in plasma levels of harpagide

    Blood will be drawn for Devil's Claws metabolites at Visit 2

    Time frame: 24 hours after dose of Devil's Claw

  3. Change in plasma levels of verbascoside

    Blood will be drawn for Devil's Claws metabolites at Visit 2

    Time frame: 24 hours after dose of Devil's Claw

  4. Change in levels of 8-p-coumarylharpagide

    Blood will be drawn for Devil's Claws metabolites at Visit 2

    Time frame: 24 hours after dose of Devil's Claw

07

Study locations

1 site
  • Univ of Missouri Health Care Center
    Columbia, Missouri 65211, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2021; primary completion for Jul 2021, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2018
First posted
Aug 21, 2018
StartEst.
May 1, 2021
Primary completionEst.
Jul 31, 2021
CompletionEst.
Aug 31, 2021
Last update
May 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03641248
Responsible party
William Folk (Professor, University of Missouri-Columbia) — Principal investigator
First posted
Aug 21, 2018
Start date
May 1, 2021 (estimated)
Primary completion
Jul 31, 2021 (estimated)
Completion
Aug 31, 2021 (estimated)
Last update
May 26, 2022

Study contacts

William Folk, PhD
principal investigator · Univ of Missouri

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Harpagophytum procumbens

Start the discussion